In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

Growing Pipelines, Promising Candidates Bring Gene Therapy To The Next Level

Advances in gene therapy have created a dynamic pipeline. A recent Datamonitor Healthcare report examines various trends in that pipeline, including vector types used, in vivo versus ex vivo approaches, and therapy areas being targeted.

Regenerative Medicine Market Intelligence
Advertisement

Latest From Market Intelligence

Biopharma Quarterly Dealmaking Statistics, Q2 2018

Biopharma financing for the second quarter totaled $12.4 billion, a 25% decrease from Q1 2018. Meanwhile Q2 merger and acquisition deal value reached $101 billion, three-quarters of which came from Takeda's $79 billion takeover of major European player Shire. Alliances – totaling $13.8 billion (a significant decline from the previous quarter's $30.7 billion) – featured large partnerships in the antibody space, the biotechnology industry sector with the highest dollar volume.

Deals Market Intelligence

You May Be Making These Drug Forecasting Mistakes

What are the top 10 most common drug forecasting errors, and how can these be avoided? Life sciences consulting firm, Trinity Partners, explores the ins and outs of forecasting. 

Market Intelligence Strategy

Consort Targets Complete Drug Delivery Service, But Rivals Keep Heat On

Industry activity in the drug delivery device sector is characterized more by stability than speed. Consort Medical's recent strategic moves have been both deliberate and decisive. For these players, deals with pharma can be several years in the making.

Market Intelligence Business Strategies

Deals In Depth: July 2018

Merck & Co. signed a $1.66 billion deal to license Sutro Biopharma’s immune-modulating cytokine derivatives in oncology and autoimmune disease. Boston Scientific announced two acquisitions, Claret Medical in the embolic protection space, and Cryterion Medical, a cryoablation company. Biopharma and device financing slowed down in July.

Deals Financing

Deals Shaping The Medical Industry, August 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in July 2018.

Deals BioPharmaceutical

How To Establish Yourself As A Digital Front-Runner – A Perspective

Biopharma and medtech companies are using patient information across the product lifecycle to make evidence generation agile and virtual, and to move beyond single products toward end-to-end patient management. 

Digital Health Business Strategies
See All
UsernamePublicRestriction

Register